NCT07011823View on ClinicalTrials.gov

Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2033

Conditions
Triple-Negative Breast Neoplasm
Interventions
RADIATION

Partial breast-irradiation

"First, 8Gy partial breast irradiation will be delivered in immune-cold triple-negative breast cancer (TNBC) confirmed by PD-L1 and TILs.~Sequentially, standard neoadjuvant chemotherapy for triple-negative breast cancer including pembrolizumab, paclitaxel, carboplatin, doxorubicin, and cyclophosphamide (KeyNote-522 regimen) will be administered, followed by surgical treatment."

All Listed Sponsors
lead

Gangnam Severance Hospital

OTHER